Perhaps, the anti-tumorigenic capabilities of HuR blockade could also be harnessed for CAC through the combinatorial-yet carefully controlled—use of anti-inflammatory drugs or drugs inhibiting the recruitment of myeloid-derived cells in the mucosa, alongside HuR inhibition regimes; or devise strategies for the selective uptake of HuR inhibitors by cancer cells thus bypassing the adverse targeting of myeloid-derived compartments. Here, ELAVL1 is linked to cancer.